HOME >> BIOLOGY >> NEWS
ChemGenex uses genomics approach to develop new anticancer drug, predict possible side effects

Gene expression changes in response to drugs in cell culture and living systems provide unique insights for their development and use

MENLO PARK, CA (October 30, 2001): Most genomics research is currently aimed at identifying and validating new gene targets for use in early stage drug discovery. However, genomics can also play a key role now in preclinical and clinical drug development, including predicting potential drug toxicities and helping developers design clinical trials, say scientists from ChemGenex Therapeutics. They discussed data today illustrating the use of chemical genomics approaches in evaluating the potential of their investigational drug called Ceflatonin against leukemias and human solid tumors. The researchers presented their findings at the American Association of Cancer Research National Cancer Institute European Organization for Research and Treatment of Cancer conference on Molecular Targets and Cancer Therapeutics taking place from October 29 to November 3 in Orlando, Florida.

Understanding how genes perform in response to chemicals in cell cultures, as well as in diseased and normal tissues in living systems can help researchers identify and evaluate potential new drugs more efficiently than ever before, said Dennis Brown, Ph.D., chairman, chief executive officer and founder of ChemGenex Therapeutics, Inc.

Such knowledge can help spotlight possible drug toxicities, as well as identify which patients may best benefit from treatment with a specific drug, he continued. In addition, chemical genomics can aid in the design of efficient clinical trials by helping trial designers predict the most effective doses and dose scheduling, as well as provide key insights into drug bioavailability, distribution and metabolism. Using genomics in this way to help patients receive most effectively those medicines that will be most useful to them is a major goal of the genomics revolution.

Based on its chem
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
30-Oct-2001


Page: 1 2 3

Related biology news :

1. International symposium on nutritional genomics
2. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics
3. Full promise of genomics in disease research yet to be realized
4. Pharmacogenomics could replace trial-and-error with science from the human genome
5. Dartmouth Medical School awarded $9 million grant for genomics research
6. Functional genomics enables easy target identification and drives drug discovery
7. Library on a Slide: Whole genome microarrays for comparative genomics
8. New genomics tool boosts diabetes research
9. Bacteriophage genomics approach to antimicrobial drug discovery published in Nature Biotechnology
10. Emerging frontiers genomics grant for blue-green bacteria
11. What can the genomics revolution teach us about global change?

Post Your Comments:
(Date:8/4/2015)... ALBANY, N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) ... June 30, 2015. Highlights: , Second quarter ... increase from 2014 , Adjusted contract margins of ... EPS of $0.22, including a $0.05 decrease in EPS from royalties ... of $16 million "We are very pleased to ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
(Date:7/31/2015)... 31 de julio de 2015 La 10 th ... celebrará por medio de BGI del 22 al 25 de octubre ... Este año, la conferencia celebra su décimo aniversario. ... convertido en una de las reuniones anuales más influyentes del ... las reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
(Date:8/31/2015)... Aug. 31, 2015 MabVax Therapeutics Holdings, Inc. ... that the Company,s lead antibody, HuMab 5B1, will be ... presentations during the upcoming World Molecular Imaging Congress (WMIC) ... 2-5, 2015. Researchers from the Department of Radiology at ... on the use of MabVax,s lead antibody as a ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Middle East & Africa Biomedical Sensors Market ... their offering. The Middle ... estimated at $0.84 billion by 2018 at a CAGR ... near future will bring Biomedical sensors that are adaptable ...
(Date:8/31/2015)... SYDNEY , Aug. 31, 2015  US-Australian ... NVGN ) today confirmed its comprehensive scientific ... ground-breaking technology platforms in areas of unmet patient ... through the remaining preclinical projects prior to entering ... lead compounds. Acting Chief Executive Officer, ...
(Date:8/31/2015)... 2015 Trimb Healthcare AB ("Trimb") today announced ... Group BV ("YouMedical"), a Dutch OTC company with operations ... of approximately EUR 16 million, with solid growth and ... ambition is to build a leading international OTC company, ... goal. YouMedical gives us a stronger North European OTC ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
Cached News: